OTCMKTS:OCPNY Olympus (OCPNY) Stock Price, News & Analysis $18.00 -0.25 (-1.37%) As of 01/31/2023 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Olympus Stock (OTCMKTS:OCPNY) Get Olympus alerts:Sign Up Key Stats Today's Range$18.00▼$18.0050-Day Range$18.00▼$18.0052-Week Range$16.80▼$74.99Volume400 shsAverage Volume860,265 shsMarket Capitalization$23.15 billionP/E Ratio21.95Dividend Yield0.44%Price TargetN/AConsensus RatingBuy Company Overview Olympus Corporation is a Tokyo-headquartered manufacturer specializing in medical and scientific imaging, precision optics and related equipment. The company's medical systems business is focused on endoscopic technologies and therapeutic devices used in minimally invasive diagnosis and treatment, supplying hospitals and clinical facilities with endoscopes, visualization platforms and accessories. In addition to healthcare, Olympus serves scientific and industrial customers with microscopes, imaging systems, non-destructive testing equipment and precision measurement tools used in research, manufacturing and quality control. In recent years the company completed a strategic refocus on healthcare and scientific solutions, divesting its consumer camera business in 2020 to concentrate resources on medical device development, services and life-science applications. Olympus emphasizes research and development, regulatory compliance and post-sale support, providing training, maintenance and repair services alongside its product portfolio. Its offerings address a range of clinical specialties and laboratory needs, reflecting a shift toward recurring revenue streams tied to consumables, procedures and service contracts. Olympus operates globally through regional subsidiaries and distribution networks across Japan, the Americas, Europe and Asia-Pacific, serving hospitals, research institutions and industrial customers worldwide. The company is managed from its Tokyo headquarters and maintains manufacturing, R&D and service operations in multiple countries to support product development and local market requirements. Olympus's business orientation positions it as a specialist provider of imaging and diagnostic tools rather than a consumer electronics brand.AI Generated. May Contain Errors. Read More Olympus Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks12th Percentile Overall ScoreOCPNY MarketRank™: Olympus scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.7 / 5Analyst RatingBuy Consensus RatingOlympus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageOlympus has only been the subject of 1 research reports in the past 90 days.Read more about Olympus' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings Growth-47.27% Earnings GrowthEarnings for Olympus are expected to decrease by -47.27% in the coming year, from $1.65 to $0.87 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Olympus is 21.95, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.58.Price to Earnings Ratio vs. SectorThe P/E ratio of Olympus is 21.95, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.09.Price to Earnings Growth RatioOlympus has a PEG Ratio of 1.07. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioOlympus has a P/B Ratio of 5.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for OCPNY. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldOlympus has a dividend yield of 0.43%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthOlympus does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Olympus is 9.76%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Olympus will have a dividend payout ratio of 9.20% next year. This indicates that Olympus will be able to sustain or increase its dividend.Read more about Olympus' dividend. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Olympus this week, compared to 0 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Olympus insiders have not sold or bought any company stock.Percentage Held by Institutions0.03% of the stock of Olympus is held by institutions.Read more about Olympus' insider trading history. Receive OCPNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Olympus and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OCPNY Stock News HeadlinesOlympus (OTCMKTS:OCPNY) Stock Crosses Below 200-Day Moving Average - Should You Sell?May 21 at 3:31 AM | americanbankingnews.comOlympus (OTCMKTS:OCPNY) Stock Crosses Below Two Hundred Day Moving Average - What's Next?May 13, 2026 | americanbankingnews.comA 17-year investing experiment investigated in DublinPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business. | Porter & Company (Ad)Olympus Corporation (OLYMY) Q1 2026 Earnings Call TranscriptAugust 9, 2025 | seekingalpha.comOlympus Corporation (OLYMY) Q4 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comMonroe Capital Supports Olympus Partners' Acquisition of Accelevation Holding Company, LLCFebruary 18, 2025 | businesswire.comOlympus Corporation (OLYMY) Q3 2025 Earnings Call TranscriptFebruary 14, 2025 | seekingalpha.comOlympus Corporation (OLYMY) Q2 2025 Earnings Call TranscriptNovember 9, 2024 | seekingalpha.comSee More Headlines OCPNY Stock Analysis - Frequently Asked Questions How have OCPNY shares performed this year? Olympus' stock was trading at $18.00 at the beginning of the year. Since then, OCPNY shares have increased by 0.0% and is now trading at $18.00. How were Olympus' earnings last quarter? Olympus Co. (OTCMKTS:OCPNY) released its quarterly earnings results on Thursday, August, 5th. The company reported $0.13 EPS for the quarter, beating analysts' consensus estimates of $0.10 by $0.03. The company had revenue of $1.75 billion for the quarter, compared to analysts' expectations of $1.49 billion. Olympus had a trailing twelve-month return on equity of 24.30% and a net margin of 13.80%. Does Olympus have any subsidiaries? The following companies are subsidiaries of Olympus: FH ORTHO SAS, Arc Medical Design Limited, Image Stream Medical Inc, Spirus Medical Inc., Innov-X Systems Inc., Advalytix AG, AIZU OLYMPUS CORPORATION, and others. How do I buy shares of Olympus? Shares of OCPNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/05/2021Today5/22/2026Fiscal Year End3/31/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Structural clay products Sub-IndustryN/A Current SymbolOTCMKTS:OCPNY CIKN/A Webwww.olympus-global.com Phone(133) 340-2111Fax813-3340-2062Employees31,557Year Founded1919Profitability EPS (Trailing Twelve Months)$0.82 Trailing P/E Ratio21.95 Forward P/E Ratio10.91 P/E Growth1.07Net Income$1.03 billion Net Margins13.80% Pretax MarginN/A Return on Equity24.30% Return on Assets9.30% Debt Debt-to-Equity Ratio0.59 Current Ratio1.99 Quick Ratio1.48 Sales & Book Value Annual Sales$7.74 billion Price / Sales2.99 Cash Flow$1.22 per share Price / Cash Flow14.76 Book Value$3.50 per share Price / Book5.14Miscellaneous Outstanding Shares1,285,890,000Free FloatN/AMarket Cap$23.15 billion OptionableNot Optionable Beta0.70 Social Links The 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (OTCMKTS:OCPNY) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersSystem failure: The strongest leverage for gold…$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredI had never heard of this 1888 accountAn investment account dating back to 1888 has quietly delivered average annual returns of 29% over the last 25...The Oxford Club | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSpaceX controls two-thirds of all satellites - and it is about to go publicSpaceX is targeting an IPO on June 11th, with trading set to begin June 12th and the roadshow kicking off June...NXT Wave Research | SponsoredHow to Profit from Elon’s AI lab before it goes publicElon Musk's AI lab has partnered with the Department of Defense, Oracle, and Palantir - and he just filed conf...InvestorPlace | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Olympus Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Olympus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.